melanoma
BMS therapeutic cancer vaccine given swift FDA appraisal
September 29, 2014Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, Vaccine, bristol myers-squibb, keytruda, melanoma, opdivo
Bristol-Myers Squibb has been granted a speedy review for its new cancer immunotherapy drug Opdivo by the FDA for patients …
GSK melanoma drug sees quick NICE nod
September 18, 2014Sales and Marketing Cancer, GSK, NICE, Tafinlar, Yervoy, dabrafenib, melanoma, skin cancer
NICE is recommending GlaxoSmithKline’s new melanoma treatment Tafinlar (dabrafenib) after the firm offered a discount for its medicine. In final …
Merck surprise winner in PD-1 race
September 5, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, Merck, melanoma, pd-1
Merck has become the first company to bring a new class of cancer drug to the US market after the …
US rivals Pfizer and Merck team up for lung cancer
August 27, 2014Medical Communications, Research and Development, Sales and Marketing Merck, NSCLC, Roche, Xalkori, melanoma, pembrolizumab
The two biggest rival US pharma firms have joined forces to help develop a new combination treatment for certain non-small …
GSK melanoma drugs beat rival in new study
July 18, 2014Sales and Marketing GSK, Roche, Tafinlar, Yervoy, Zelboraf, mekinist, melanoma
GlaxoSmithKline’s new combination melanoma treatment has bested Roche’s established oncology drug Zelboraf when treating patients with the deadliest form of …
Roche combination drug for melanoma impresses
July 14, 2014Research and Development, Sales and Marketing GSK, Roche, Yervoy, braf, mekinist. MEK, melanoma
Roche’s investigational melanoma drug cobimetinib has helped late-stage patients live longer when used in combination with its established skin cancer …
World’s first anti-PD-1 therapy approved
July 8, 2014Research and Development, Sales and Marketing BMS, Cancer, melanoma, nivolumab, ono, opdivo
Ono Pharmaceutical has been given the world’s first licence for a new type of cancer treatment on which many researchers’ …
Mekinist shown EU green light
July 7, 2014Sales and Marketing CHMP, Cancer, GSK, Tafinlar, braf, mekinist, melanoma
The European Commission has given GlaxoSmithKline’s melanoma drug Mekinist the thumbs-up following a positive opinion in April from the European …
PD-1 cancer race heats up as Merck takes lead
July 2, 2014Research and Development, Sales and Marketing ASCO, Cancer, Merck, melanoma, mk3475, oncology, pembrolizumab
Merck’s oncology drug pembrolizumab has taken a big step towards becoming Europe’s first PD-1 cancer treatment as the EMA accepts …
New BMS cancer treatment shines
June 25, 2014Research and Development, Sales and Marketing ASCO, BMS, Cancer, Yervoy, braf, melanoma, nivolumab
Bristol-Myers Squibb’s investigational cancer treatment nivolumab has helped patients with the deadliest form of skin cancer to live longer. The …
NICE recommends Yervoy
June 13, 2014Sales and Marketing BMS, Cancer, Dillon, NHS, NICE, Yervoy, melanoma
Bristol-Myers Squibb has received a lift from the UK’s drugs watchdog, which has recommended its vaccine Yervoy as a first-line …
Merck drug shines at ASCO
June 4, 2014Research and Development, Sales and Marketing ASCO, Cancer, FDA, MK-3475, Merck, melanoma
Merck has shown off one of its investigative cancer drug’s impressive results in advanced head and neck cancer at ASCO …
GSK cancer vaccine fails again
March 20, 2014Sales and Marketing Cancer, GSK, MAGE-A3 cancer immunotherapeutic, NSCLC, lung cancer, melanoma
GlaxoSmithKline’s MAGE-A3 cancer immunotherapeutic has delivered another late-stage blow to the firm but it still vows to continue trials. The …
Amgen melanoma vaccine shrinks tumours
March 17, 2014Research and Development, Sales and Marketing Amgen, Cancer, Yervoy, melanoma, t-vec
Amgen’s investigational cancer vaccine T-vec has managed to shrink the size of advanced melanoma tumours in a late-stage trial. The …
NICE restricts Yervoy use
February 25, 2014Sales and Marketing BMS, Cancer, NHS, NICE, Yervoy, melanoma
Bristol-Myers Squibb has been dealt a blow by NICE after the UK cost watchdog recommended that the use of skin …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
